Bristol Myers Squibb (BMS) has reported full-year 2025 revenues of $48.2bn, essentially flat compared with $48.3bn in 2024.

FDA commissioner Marty Makary’s pledge came after Hims & Hers launched a compounded version of Novo’s Wegovy pill.

President Donald Trump has unveiled his TrumpRx website, offering over 40 drugs at steeply discounted prices to cash-paying ...

Medicine prices are facing increasing pricing pressure—and early 2026 is one of the first notable periods where the list ...

PrimeGen US and DT Cloud Star Acquisition have entered a definitive merger agreement at an implied equity value of around $1.5bn.

Everest Medicines has signed an exclusive licence agreement with Micot to commercialise MT1013 in China and the Asia Pacific ...

After more than a year out in the cold, the programme’s reauthorisation is a boost for rare disease therapy developers.

Eisai will now take ownership of the Japanese rights to Henlius' differentiated anti-PD-1 therapy, Hetronifly (serplulimab).

Apotex and Grünenthal have finalised a licensing agreement granting Apotex exclusive Canadian rights to Nebido, a long-acting ...

The upcoming patent cliff, the impact of geopolitical and policy issues, and a changing deal environment were discussed at ...